EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mutations in latent membrane protein 1 of Epstein-Barr virus are associated with increased risk of posttransplant lymphoproliferative disorder in children

Olivia M Martinez, Sheri M Krams, Mark A Robien, Mary G Lapasaran, Matthew P Arvedson, Andrea Reitsma, Yarl Balachandran, Aleishia Harris-Arnold, Kenneth Weinberg, Scott D Boyd, Brian Armstrong, Amber Trickey und 12 weitere

American Journal of Transplantation · 2023

DOI: 10.1016/j.ajt.2023.02.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Transplantation, 2023. Verfasst von Olivia M Martinez und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Stanford University School of Medicine, Palo Alto, California, USA; Stanford Immunology, Stanford University School of Medicin…. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Lymphoproliferative Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epstein-Barr virus (EBV)-positive posttransplant lymphoproliferative disorder (PTLD) results in significant morbidity and mortality in pediatric transplant recipients. Identifying individuals at an increased risk of EBV-positive PTLD could influence clinical management of immunosuppression and other therapies, improving posttransplant outcomes. A 7-center prospective, observational clinical trial of 872 pediatric transplant recipients evaluated the presence of mutations at positions 212 and 366 of EBV latent membrane protein 1 (LMP1) as an indicator of risk of EBV-positive PTLD (clinical trials: NCT02182986). DNA was isolated from peripheral blood of EBV-positive PTLD case patients and matched controls (1:2 nested case:control), and the cytoplasmic tail of LMP1 was sequenced. Thirty-four participants reached the primary endpoint of biopsy-proven EBV-positive PTLD. DNA was sequenced from 32 PTLD case patients and 62 matched controls. Both LMP1 mutations were present in 31 of 32 PTLD cases (96.9%) and in 45 of 62 matched controls (72.6%) (P = .005; OR = 11.7; 95% confidence interval, 1.5, 92.6). The presence of both G212S and S366T carries a nearly 12-fold increased risk of development of EBV-positive PTLD. Conversely, transplant recipients without both LMP1 mutations carry a very low risk of PTLD. Analysis of mutations at positions 212 and 366 of LMP1 can be informative in stratifying patients for risk of EBV-positive PTLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsLymphoproliferative DisordersHumansChildHerpesvirus 4, HumanProspective StudiesMutationMembrane Proteins

Stichwörter der Autor:innen

B cell lymphomaEBVLMP1PTLDpediatric transplantation

Substanzen

Membrane Proteins

Autor:innen und Institutionen

  • Department of Surgery, Stanford University School of Medicine, Palo Alto, California, USA; Stanford Immunology, Stanford University School of Medicine, Palo Alto, California, USA. Electronic address: omm@stanford.edu.
  • Department of Surgery, Stanford University School of Medicine, Palo Alto, California, USA; Stanford Immunology, Stanford University School of Medicine, Palo Alto, California, USA.
  • National Institute of Allergy and Infectious Disease, Rockville, Maryland, USA.
  • Department of Surgery, Stanford University School of Medicine, Palo Alto, California, USA.
  • Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Martinez, O. M., Krams, S. M., Robien, M. A., Lapasaran, M. G., Arvedson, M. P., Reitsma, A., Balachandran, Y., Harris-Arnold, A., Weinberg, K., Boyd, S. D., Armstrong, B., Trickey, A., Twist, C. J., Gratzinger, D., Tan, B., Brown, M., Chin, C., Desai, D. M., Fishbein, T. M., …, & Esquivel, C. O. (2023). Mutations in latent membrane protein 1 of Epstein-Barr virus are associated with increased risk of posttransplant lymphoproliferative disorder in children. American Journal of Transplantation. https://doi.org/10.1016/j.ajt.2023.02.014

Vancouver

Martinez OM, Krams SM, Robien MA, Lapasaran MG, Arvedson MP, Reitsma A, et al. Mutations in latent membrane protein 1 of Epstein-Barr virus are associated with increased risk of posttransplant lymphoproliferative disorder in children. American Journal of Transplantation. 2023. doi:10.1016/j.ajt.2023.02.014

BibTeX
@article{Martinez2023,
  author = {Martinez, Olivia M and Krams, Sheri M and Robien, Mark A and Lapasaran, Mary G and Arvedson, Matthew P and Reitsma, Andrea and Balachandran, Yarl and Harris-Arnold, Aleishia and Weinberg, Kenneth and Boyd, Scott D and Armstrong, Brian and Trickey, Amber and Twist, Clare J and Gratzinger, Dita and Tan, Brent and Brown, Merideth and Chin, Clifford and Desai, Dev M and Fishbein, Thomas M and Mazariegos, George V and Tekin, Akin and Venick, Robert S and Bernstein, Daniel and Esquivel, Carlos O},
  title = {Mutations in latent membrane protein 1 of Epstein-Barr virus are associated with increased risk of posttransplant lymphoproliferative disorder in children},
  journal = {American Journal of Transplantation},
  year = {2023},
  doi = {10.1016/j.ajt.2023.02.014}
}
Kostenlos starten →